Senti Biosciences (NASDAQ:SNTI) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Senti Biosciences (NASDAQ:SNTI – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.16), reports.

Senti Biosciences Trading Down 0.4%

NASDAQ SNTI traded down $0.00 on Wednesday, reaching $0.10. 160,373 shares of the stock were exchanged, compared to its average volume of 1,181,995. Senti Biosciences has a one year low of $0.09 and a one year high of $2.88. The firm has a market capitalization of $3.01 million, a PE ratio of -0.05 and a beta of 2.31. The company’s 50-day simple moving average is $0.25 and its two-hundred day simple moving average is $0.67.

Senti Biosciences’s stock is set to reverse split on Thursday, November 19th. The 1-33 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, November 18th.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

View Our Latest Research Report on Senti Biosciences

About Senti Biosciences

(Get Free Report)

Senti Biosciences is a biotechnology company focused on developing cell and gene therapies using synthetic biology. Its platform uses engineered gene circuits designed to help therapeutic cells recognize disease-related signals and respond in a controlled way. The company has worked on engineered immune-cell treatments, including allogeneic CAR-NK candidates. Its pipeline has included programs aimed at blood cancers and solid tumors, such as SENTI-202 and SENTI-301A. Founded in 2016 and based in South San Francisco, California, Senti Biosciences has concentrated its research and development activities in the United States.

See Also

Earnings History for Senti Biosciences (NASDAQ:SNTI)

Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.